Not Yet RecruitingNot Applicable

Predictive Value of CEA and ctDNA in Lung Cancer Recurrence

100 participantsStarted 2025-09-15

Plain-language summary

The study aims to investigate the predictive value of CEA levels for postoperative recurrence in the highly sensitive CEA lung cancer patients and to explore whether the dynamic changes of postoperative CEA and MRD in this population are related.This study was carried out to accurately predict the recurrence time, save the time and cost of changing the intervention strategy, and provide more personalized treatment for patients.

Who can participate

Age range15 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Preoperative CEA \> 5mg/l
✓. MRD testing was conducted before the operation
✓. The primary lesion was resected through surgery
✓. There should be at least two CEA and MRD follow-up tests within 2 years after the operation
✓. Postoperative pathology confirmed it as a malignant lung tumor

Exclusion criteria

✕. Those without available imaging records
✕. Patients with a history of malignant tumors within the past five years
✕. Patients with secondary lung cancer

What they're measuring

Postoperative tumor recurrence or progression

Timeframe: 2 years

Trial details

NCT IDNCT07170046

SponsorGuangdong Provincial People's Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-08-01

View on ClinicalTrials.gov More Lung Carcinoma trials